China’s National Medical Products Administration (NMPA) approved two differentiated therapies aimed at reducing acute and seasonal disease burden. Everest Medicines’ Cardamyst became a self-administered nasal spray for paroxysmal supraventricular tachycardia, while Simcere Pharmaceutical Group’s Yingmule gained approval as a long-acting monoclonal antibody to prevent RSV-related lower respiratory tract infections in newborns and infants. The approvals add to China’s growing roster of differentiated delivery methods and long-acting prevention products. Cardamyst’s self-administration angle targets usability in acute rhythm episodes, while Yingmule addresses a high-need pediatric prevention segment. Strategically, the pair of NMPA decisions reflects ongoing emphasis on differentiated administration and prophylaxis in addition to oncology-focused approvals. For manufacturers, regulatory clearance also enables smoother scaling of launch plans tied to seasonal RSV dynamics and acute care pathways for arrhythmias.